Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 24, 2017 16:21 ET | Source: Neos Therapeutics, Inc.

Neos Therapeutics to Present Two Posters on Company’s ADHD Medications at the American Academy of Child & Adolescent Psychiatry Meeting

DALLAS/FORT WORTH, Texas, Oct. 24, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS) today announced that it will present two posters at the 64th Annual Meeting of the American Academy...
October 18, 2017 08:00 ET | Source: Neos Therapeutics, Inc.

Neos Therapeutics Announces Settlement with Actavis on Adzenys XR-ODT® Patent Litigation

DALLAS and FORT WORTH, Texas, Oct. 18, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing, and commercializing innovative...
October 02, 2017 08:00 ET | Source: Neos Therapeutics, Inc

Neos Therapeutics Announces US Launch of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old

DALLAS/FORT WORTH, Texas, Oct. 02, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
September 15, 2017 16:39 ET | Source: Neos Therapeutics, Inc

Neos Therapeutics Receives U.S. FDA Approval of Adzenys ER™ (amphetamine) Extended-Release Oral Suspension for the Treatment of ADHD in Patients 6 Years and Older

DALLAS and FORT WORTH, Texas, Sept. 15, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
September 05, 2017 08:00 ET | Source: Neos Therapeutics, Inc

Neos Therapeutics Announces Launch of Cotempla XR-ODT™ (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old

DALLAS and FORT WORTH, Texas, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
August 30, 2017 07:30 ET | Source: Neos Therapeutics, Inc

Neos Therapeutics to Participate in Three September Conferences

DALLAS and FORT WORTH, Texas, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
August 08, 2017 07:00 ET | Source: Neos Therapeutics, Inc

Neos Therapeutics Reports Second Quarter 2017 Financial Results

DALLAS and FORT WORTH, Texas, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
August 02, 2017 07:30 ET | Source: Neos Therapeutics, Inc

Neos Therapeutics to Host Second Quarter 2017 Financial Results Conference Call on August 8, 2017

DALLAS and FORT WORTH, Texas, Aug. 02, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
June 27, 2017 08:59 ET | Source: Neos Therapeutics, Inc

Neos Therapeutics Announces Pricing of Underwritten Public Offering of $32.4 Million of Common Stock

DALLAS and FORT WORTH, Texas, June 27, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...
June 26, 2017 16:01 ET | Source: Neos Therapeutics, Inc

Neos Therapeutics Announces Proposed Offering of Common Stock

DALLAS and FORT WORTH, Texas, June 26, 2017 (GLOBE NEWSWIRE) -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right